149 related articles for article (PubMed ID: 31501796)
1. Improving the diagnosis of high grade and stage bladder cancer by detecting increased urinary calprotectin expression in tumor tissue and tumor-associated inflammatory response.
Sahin Y; Yucetas U; Ates HA; Erkan E; Yucetas E; Temiz MZ; Toktas MG; Kadihasanoglu M; Topkaya BC
Investig Clin Urol; 2019 Sep; 60(5):343-350. PubMed ID: 31501796
[TBL] [Abstract][Full Text] [Related]
2. Significance of S100A8, S100A9 and calprotectin levels in bladder cancer.
Yasar O; Akcay T; Obek C; Turegun FA
Scand J Clin Lab Invest; 2017 Oct; 77(6):437-441. PubMed ID: 28609200
[TBL] [Abstract][Full Text] [Related]
3. Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer.
Bausch K; Roth E; Heinz S; Horst D; Mathia S; Vlajnic T; Bubendorf L; Westhoff T; Wetterauer C; Seifert HH; Ebbing J
PLoS One; 2019; 14(3):e0213549. PubMed ID: 30870488
[TBL] [Abstract][Full Text] [Related]
4. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.
Ebbing J; Mathia S; Seibert FS; Pagonas N; Bauer F; Erber B; Günzel K; Kilic E; Kempkensteffen C; Miller K; Bachmann A; Rosenberger C; Zidek W; Westhoff TH
World J Urol; 2014 Dec; 32(6):1485-92. PubMed ID: 24378824
[TBL] [Abstract][Full Text] [Related]
5. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
[TBL] [Abstract][Full Text] [Related]
6. The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma.
Soukup V; Capoun O; Pesl M; Vavrova L; Sobotka R; Levova K; Hanus T; Zima T; Kalousova M
Neoplasma; 2019 Nov; 66(6):1019-1023. PubMed ID: 31607136
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer.
Arikan O; Yýldýrým A; Ýsbilen B; Canakci C; Atýs G; Gurbuz C; Erol B; Ýsman FK; Ozkanli S; Caskurlu T
Int Braz J Urol; 2015; 41(6):1080-7. PubMed ID: 26742964
[TBL] [Abstract][Full Text] [Related]
8. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
9. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Urology; 2001 Apr; 57(4):675-9. PubMed ID: 11306379
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
11. Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury.
Westhoff JH; Seibert FS; Waldherr S; Bauer F; Tönshoff B; Fichtner A; Westhoff TH
Eur J Pediatr; 2017 Jun; 176(6):745-755. PubMed ID: 28409285
[TBL] [Abstract][Full Text] [Related]
12. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
13. Comparison of p38MAPK (mitogene activated protein kinase), p65 NFkappaB (nuclear factor kappa b) and EMMPRIN (extracellular matrix metalloproteinase inducer) expressions with tumor grade and stage of superficial and invasive bladder tumors.
Ozbek E; Otunctemur A; Calik G; Aliskan T; Cakir S; Dursun M; Somay A
Arch Ital Urol Androl; 2011 Dec; 83(4):181-7. PubMed ID: 22670315
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness.
Sevcenco S; Ponhold L; Heinz-Peer G; Fajkovic H; Haitel A; Susani M; Shariat SF; Szarvas T; Baltzer PA
Urol Oncol; 2014 Nov; 32(8):1166-71. PubMed ID: 24962659
[TBL] [Abstract][Full Text] [Related]
15. Urinary Calprotectin Differentiates Between Prerenal and Intrinsic Acute Renal Allograft Failure.
Seibert FS; Rosenberger C; Mathia S; Arndt R; Arns W; Andrea H; Pagonas N; Bauer F; Zidek W; Westhoff TH
Transplantation; 2017 Feb; 101(2):387-394. PubMed ID: 26901081
[TBL] [Abstract][Full Text] [Related]
16. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
17. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
19. Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.
Zhang G; Gomes-Giacoia E; Dai Y; Lawton A; Miyake M; Furuya H; Goodison S; Rosser CJ
Diagn Pathol; 2014 Nov; 9():200. PubMed ID: 25387487
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
